

OCT. 5. 2006 4:27PM LVM 312 616 5700

RECEIVED
CENTRAL FAX CENTER

NO. 3836 P. 5

Application No. 10/825,531

OCT 05 2006


Reply to Office Action

AMENDMENTS TO THE CLAIMS


This listing of claims replaces all prior versions, and listings, of claims in the application.

1.-18. (Canceled)

19. (New) A compound selected from the group consisting of (a)




and (b) pharmaceutically acceptable salts, hydrates, and solvates of




20. (New) The compound of claim 19, wherein the compound is

Application No. 10/825,531


Reply to Office Action



21. (New) A composition comprising (i) a compound selected from the group consisting of (a)



and (b) pharmaceutically acceptable salts, hydrates, and solvates of




and (ii) a pharmacologically acceptable carrier.

Application No. 10/825,531


Reply to Office Action

22. (New) The composition of claim 21, wherein the compound is




23. (New) A method of inhibiting cholesterol ester transfer protein (CETP) activity in a patient, which method comprises administering to the patient a composition comprising

(i) a compound selected from the group consisting of (a)



and (b) pharmaceutically acceptable salts, hydrates, and solvates of



, and


Application No. 10/825,531

Reply to Office Action

(ii) a pharmacologically acceptable carrier,


whereby CETP activity is inhibited in the patient.

24. (New) The method of claim 23, wherein the compound is



25. (New) A method of increasing high density lipoprotein (HDL) in a patient, which method comprises administering to the patient a composition comprising


(i) a compound selected from the group consisting of (a)



and (b) pharmaceutically acceptable salts, hydrates, and solvates of

Application No. 10/825,531

Reply to Office Action




, and

(ii) a pharmacologically acceptable carrier,


whereby HDL is increased in the patient.

26. (New) The method of claim 25, wherein the compound is



27. (New) A method of treating or preventing atherosclerosis in a patient, which method comprises administering to the patient a composition comprising


(i) a compound selected from the group consisting of (a)



Application No. 10/825,531

Reply to Office Action

and (b) pharmaceutically acceptable salts, hydrates, and solvates of




, and

(ii) a pharmacologically acceptable carrier,

whereby atherosclerosis is treated or prevented in the patient.

28. (New) The method of claim 27, wherein the compound is




29. (New) A method of treating or preventing hyperlipidemia in a patient, which method comprises administering to the patient a composition comprising


(i) a compound selected from the group consisting of (a)

Application No. 10/825,531

Reply to Office Action



and (b) pharmaceutically acceptable salts, hydrates, and solvates of




, and

(ii) a pharmacologically acceptable carrier,

whereby hyperlipidemia is treated or prevented in the patient.


30. (New) The method of claim 29, wherein the compound is



31. (New) A method of inhibiting cholesterol ester transfer protein (CETP) activity in a patient, which method comprises providing


Application No. 10/825,531

Reply to Office Action




in vivo, whereby CETP activity is inhibited in the patient.

32. (New) A method of increasing high density lipoprotein (HDL) in a patient, which method comprises providing



in vivo, whereby HDL is increased in the patient.

33. (New) A method of treating or preventing atherosclerosis in a patient, which method comprises providing




Application No. 10/825,531

Reply to Office Action


in vivo, whereby atherosclerosis is treated or prevented in the patient.

34. (New) A method of treating or preventing hyperlipidemia in a patient, which method comprises providing




in vivo, whereby hyperlipidemia is treated or prevented in the patient.

35. (New) A method of preparing a compound of formula (1)



(1)

wherein R₁ is C₁₋₁₀ alkyl, wherein the method comprises reacting



Application No. 10/825,531

Reply to Office Action


with an acid halide of formula (2)

in the presence of a base, wherein R_1 is as described above and X is Cl, Br, or I.

36. (New) The method of claim 35, wherein the reaction is conducted in the presence of an organic solvent, water, or a mixture thereof.


37. (New) The method of claim 35, wherein R_1 is $-CH(CH_3)_2$.

38. (New) A method of preparing a compound of formula (1)

wherein R_1 is C_{1-10} alkyl, wherein the method comprises reacting

Application No. 10/825,531

Reply to Office Action



with an organic acid of formula (3)



in the presence of a coupling agent, wherein R_1 is as described above and Y is O or S.

39. (New) The method of claim 38, wherein the reaction is conducted in the presence of an activating agent.

40. (New) The method of claim 38, wherein the reaction is conducted in the presence of an organic solvent.


41. (New) The method of claim 38, wherein the reaction is conducted in the presence of a base.

42. (New) The method of claim 38, wherein R_1 is $-CH(CH_3)_2$.

43. (New) A method of preparing a compound of formula (1)


Application No. 10/825,531

Reply to Office Action



(1)

wherein R₁ is C₁₋₁₀ alkyl, wherein the method comprises reacting



with a carboxylic acid of formula (4)



in the presence of a base and ethyl chlorocarbonate, wherein R₁ is as described above.

44. (New) The method of claim 43, wherein the reaction is conducted in the presence of an organic solvent.

45. (New) The method of claim 43, wherein R₁ is -CH(CH₃)₂.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.